Verona Pharma Q2 2023 Earnings Report $41.54 -0.12 (-0.29%) (As of 12:45 PM ET) Earnings HistoryForecast Verona Pharma EPS ResultsActual EPS-$0.11Consensus EPS -$0.27Beat/MissBeat by +$0.16One Year Ago EPSN/AVerona Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVerona Pharma Announcement DetailsQuarterQ2 2023Date8/3/2023TimeN/AConference Call ResourcesPress ReleaseVRNA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Verona Pharma Earnings HeadlinesVerona Pharma (VRNA) Gets a Buy from Truist FinancialDecember 11, 2024 | markets.businessinsider.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $920,477.28 in StockDecember 9, 2024 | americanbankingnews.comUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?December 18, 2024 | Huge Alerts (Ad)Jefferies Sticks to Their Buy Rating for Verona Pharma (VRNA)December 2, 2024 | markets.businessinsider.comVerona Pharma: In COPD, There's A Corner With Their Name On ItNovember 27, 2024 | seekingalpha.comVerona Pharma Announces December 2024 Investor Conference ParticipationNovember 19, 2024 | globenewswire.comSee More Verona Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma and other key companies, straight to your email. Email Address About Verona PharmaVerona Pharma (NASDAQ:VRNA), a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.View Verona Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
